Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation

v2.4.0.6
Stock-Based Compensation
 3 Months Ended
Mar. 31, 2012
Stock-Based Compensation [Abstract]  
Stock-Based Compensation

8. Stock-based Compensation

Stock-based Compensation Plans

As of March 31, 2012, the Company has two equity compensation plans, the Coronado Biosciences, Inc. 2007 Stock Incentive Plan, for employees, non-employees and outside directors and, subject to stockholder approval, the Coronado Biosciences, Inc. 2012 Employee Stock Purchase Plan (the "ESPP"). Although the ESPP is still subject to stockholders approval, eligible employees began to participate in the ESPP effective February 1, 2012.

Compensation Expense. The following table summarizes the stock-based compensation expense from awards, including stock options and restricted Common Stock awards to employees and non-employees, and warrants to non-employees for the three months ended March 31, 2012 and 2011, and from the period June 28, 2006 (Date of Inception) to date.

 

     For the three months ended
March 31,		     

Period from

June 28, 2006

(Date of

Inception) to

March 31,

  
($ in thousands)    2012      2011      2012  

Employee awards

    $ 313       $ 99      $ 1,048   

Non-employee awards

      445         34         3,258   

Non-employee warrants

      116         77         442   
  

 

 

     

 

 

     

 

 

  

Total stock-based compensation expense

    $ 874       $ 210       $ 4,748   
  

 

 

     

 

 

     

 

 

  

 

The following table summarizes stock option activity as of March 31, 2012:

 

     Outstanding Options      Weighted
Average
Remaining
Contractual
Life (in
years)		  
($ in thousands except per share amounts)    Number of
Shares		      Weighted
Average
Exercise
Price		      Total
Weighted
Average
Intrinsic
Value		     

At December 31, 2011

      1,814,070       $ 2.17       $ 7,852         9.2   

Options granted

      390,000         6.64         

Options exercised

      —              

Options cancelled

      —              
  

 

 

           

At March 31, 2012

      2,204,070       $ 2.96       $ 12,117         9.1   
  

 

 

           

Options vested and expected to vest

      2,124,723       $ 2.96       $ 11,680         9.1   

Options vested and exercisable

      254,690       $ 1.43       $ 1,790         9.1   

As of March 31, 2012, the Company had unrecognized stock-based compensation expense related to unvested stock options granted to employees of $4.3 million, which is expected to be recognized over the remaining weighted-average vesting period of 2.1 years.